CJC-1295
A long-acting GHRH analog engineered to stretch GH pulses.
Identity
- Class
- GHRH(1-29) analog (with or without a drug-affinity complex)
- Source
- Synthetic analog of GHRH
- Receptor
- GHRH receptor (GHRHR), a class B GPCR
Key properties
Molecular weight
≈ 3,647 Da
Half-life (native)
~6-8 days (DAC form); ~30 min without DAC
Approximate values for the native hormone. Engineered analogs are often deliberately larger and far longer-acting.
Mechanism
CJC-1295 is a modified GHRH(1-29) that resists DPP-4 degradation and, in its drug-affinity-complex (DAC) form, binds circulating albumin to extend its half-life from minutes to days — sustaining GHRH-receptor stimulation and elevating GH and IGF-1 over a prolonged window. Because it drives the pituitary rather than replacing GH, secretion stays broadly pulsatile and feedback-regulated.
Reference notes
- Two forms circulate under one name: the DAC version is long-acting (days), while the widely sold 'no-DAC' form (modified GRF 1-29) acts over roughly half an hour.
- A 2006 human study showed the DAC form sustained GH and IGF-1 elevations for about a week per dose.
- It is an unapproved research compound; controlled long-term human safety and efficacy data are sparse.
Selected literature
Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.
- 1.Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · The Journal of clinical endocrinology and metabolism, 2006 · PMID 16352683
- 2.Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance · Sports medicine (Auckland, N.Z.), 2026 · PMID 41966639
- 3.Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions · Substance use & misuse, 2016 · PMID 26771670